Executive Team
George Simeon
CEO
George Simeon is the CEO of Curevo Vaccine. He joined Curevo at the beginning of 2019 and has over 30 years of experience in the healthcare sector working with multinational firms, start-ups, and not-for-profits. He has worked in biotech, pharmaceuticals, medical devices, IVD, and healthcare convergence technologies. He has worked extensively in Europe, Asia, and North America.
Before moving to the USA, he was based in South Korea from 2014-2018, where he worked for SK Telecom’s Healthcare Division in M&A and global strategic alliances. In 2016, he joined Sollers Partners, a cross-border investment advisory firm, while maintaining an advisory role with SK Telecom.
He has worked across Europe and the USA as an executive with Johnson & Johnson, as the founding Vice-President of Cordis Neurovascular Europe, and with GHX Europe as a Commercial Vice-President. He also spent 3 years with Novartis Global Headquarters in Switzerland working on projects in their CNS portfolio in Health Economics and Pricing.
George has also founded two start-ups and advised GS1 on their global entry and expansion into the Healthcare, High-Tech, and Customs sectors as well as on ESG practices in FMCG logistics.
George is a graduate of INSEAD (MBA) and Yale University (MPH).
Gregory S. Curhan
CFO
Greg Curhan has been the CFO of Curevo Vaccine since 2020. He has over 35 years of operational, financial, capital markets and strategic advisory experience in various sectors including Investment Banking, Medical Device/Life Sciences, Internet, Clean Technology, and Investment/Wealth Management. Greg has been a Partner at FLG Partners since 2020. As CFO, Greg has managed Finance, Legal, HR, and Investor Relations functions for Public and Private companies. He has raised equity and debt capital for both private and public companies, completed numerous successful IPOs, and executed M&A transactions both acquiring and divesting companies. He has also served in CEO, President and Board of Director capacities. In July 2020, Greg was appointed to the Advisory Board at Specific Diagnostics as the company prepares to launch its Reveal rapid susceptibility testing system in Europe.
Greg founded and was President of an investment bank (Merriman Curhan Ford) growing it from pre-revenue startup to 250 employees, $90 million in revenue, profitability, and a Nasdaq listing within 7 years. The investment bank raised over $5 billion dollars for corporate clients (both public and private) during that period in IPOs, Public offerings, PIPE financings and Private Placements, while also executing successful M&A engagements in various Technology, Biotech, Medical Technology and Consumer sectors.
Prior to joining FLG, Greg was CFO and SVP Corporate Development of Providence Medical Technology, a venture backed medical device manufacturer whose purpose is to improve clinical outcomes for high-risk patients and prevent surgical failures of the cervical spine. At Providence Greg raised multiple rounds of equity investment, identifying and bringing in a new lead investor in the company’s largest private round to date. He arranged new debt financing facilities, increasing the size and extending the maturity twice in three years. He introduced long term FP&A practices to support strategy formation and capital raising, including budgeting for a multi-year, randomized clinical trial.
Prior to that Greg was CEO of Clickworker USA, a US subsidiary of a venture backed German Crowdsourcing platform. He was EVP and CFO of MCF Corporation, the parent company of Merriman Curhan Ford. He was also CFO of WorldRes, a venture backed web-based hotel reservation booking engine. In addition, Greg has worked for various investment banking firms including Merrill Lynch, Montgomery Securities, Volpe Brown Whelan and MLV.
Greg earned a BA degree in Economics (summa cum Laude and Phi Beta Kappa) from Dartmouth College. He was an Adjunct Professor teaching Entrepreneurial Finance to MBA students at Dominican University and wrote and published a Novel Indomitable Spirit.
Guy De La Rosa, MD
CMO
Guy R. De La Rosa, M.D., is the Chief Medical Officer at Curevo Vaccine. He joined Curevo in 2023. Dr. De La Rosa brings over 20 years of clinical experience directing successful development programs across multiple areas in the field of Infectious Diseases. Prior to joining Curevo Vaccine, Dr. De La Rosa worked for Enanta Pharmaceuticals, where he served in roles of increasing seniority, culminating as Executive Medical Director for Infectious Diseases, and leading the clinical development for several assets for RSV, SARS-CoV-2 and HBV. Prior to his tenure at Enanta Pharmaceuticals, Dr. De La Rosa held positions with Abbott, Janssen, and Takeda Pharmaceuticals where he led the development of assets for HIV, HCV, RSV and Dengue Tetravalent Vaccine. He has co-authored and collaborated in more than 60 scientific publications and presentations.
Dr. De La Rosa earned his M.D. at the University of Panama School of Medicine. He completed his Internal Medicine Residency in Boston, MA and his Infectious Diseases Fellowship at the University of Texas/M.D. Anderson Cancer Center in Houston, TX. Upon completion of his Infectious Diseases Fellowship, Dr. De La Rosa completed a Fellowship in HIV Medicine at the University of Texas. Dr. De La Rosa also holds a Degree in Tropical Medicine from the London School of Hygiene & Tropical Medicine in the U.K.
Andrea Wang
Sr. VP CMC Operations
Andrea Wang is the Sr. VP CMC Operations of Curevo Vaccine. She joined Curevo at the beginning of 2022 and has over 20 years of experience in the Biotech industry developing therapeutic drugs including monoclonal antibodies, bispecific antibodies, recombinant protein drugs as well as ADC. Her work has been focused on the CMC development for earlier phase clinical studies as well as commercial drug manufacturing. She also had experience working with QA and RA for cGMP compliance and regulatory applications.
Before joining Curevo, Andrea worked at Aptevo as Senior Director for 3.5 years overseeing product quality and CMC activities for multiple projects. During this time, she played critical roles in obtaining FDA approval for a new dose strength of IXINITY®, for specification revision and drug product shelf-life extension. In addition, she participated in Scientific Advice meetings as CMC expert, and led various activities supporting several clinical stage programs. Prior to Joining Aptevo, Andrea worked at Silverback, Askgene, Allozyne and Corixa, and her work span from protein engineering to drug candidate screening/selections, from cGMP production to clinical sample testing. Andrea had 15 peer-reviewed publications, 2 book chapters, and more than 20 patents.
Andrea obtained her B.S. in Chemistry from Tsinghua in Beijing, China, and her Ph.D. in Biochemistry from Southern Illinois University, IL. She received her postdoctoral training in University of California, San Diego.
Emma Fritzen
VP, Operations
As Vice President of Operations, Emma is a dynamic executive with a proven track record in optimizing operational efficiency and driving strategic initiatives. Since joining Curevo in 2018, Emma has been instrumental in developing and streamlining internal processes to accelerate Curevo’s primary focus, vaccine development. Leveraging expertise acquired over years in the industry, she ensures seamless cross-functional collaboration and compliance with quality standards. Additionally, Emma oversees Program Management, Business Operations, Clinical Quality, Human Resources, and Facilities and Office Management. With a commitment to excellence and a focus on innovation, Emma plays a pivotal role in advancing the company’s mission to develop next-generation non-mRNA vaccines.
Emma received her master’s in science and public health at Tulane University. Having started her journey in the field of malaria research, Emma led the Human Challenge Center at the Center for Infectious Disease Research responsible for operating Controlled Human Malaria Trials. Her most recent role was conducting Asthma and Allergy Research. During her leisure time, Emma finds joy traveling and spending quality time with her daughters.
David Miller
VP, Strategic Communications
A former biotech analyst, David has 20+ years of experience with business strategy, communications, and business analysis focusing on technology and biotechnology industries. He led the investor relations and communications program at Angion (NASDAQ:ANGN), helping take the company public via a 2021 IPO. He held a variety of roles at Alpine Immune Sciences (NASDAQ:ALPN), helping taking the company public via a reverse merger in 2017.
During his time at Alpine BioVentures, he was the portfolio manager for their public company investment fund and helped start multiple companies on the private equity side. He’s also been a software company CEO, college professor, and advisor to multiple entrepreneurs across a variety of industries. He’s an avid sailboat racer, racing his sailboat One Life throughout the Pacific Northwest. David earned his BA in Communications from Western Washington University, honored by faculty as the department’s Top Graduate for his graduating class.